<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04080310</url>
  </required_header>
  <id_info>
    <org_study_id>YMC033</org_study_id>
    <nct_id>NCT04080310</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Combination Therapy of Moderate-intensity Statin and Ezetimibe Compared to High-intensity Statin</brief_title>
  <official_title>Efficacy and Safety of Combination Therapy of Moderate-intensity Statin and Ezetimibe Compared to High-intensity Statin: Study Protocol for a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, randomized, open-label, parallel, phase IV trial.

      The purpose of this study efficacy and safety of combination therapy of moderate-intensity
      statin and ezetimibe compared to high-intensity statin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is planned to include 272 patients with a clinical atherosclerotic cardiovascular
      disease requiring optimal statin therapy.

      After enrollment, subjects are randomized into two groups in a 1:1 manner. The combination
      therapy group will receive a single-pill combination of rosuvastatin 10 mg and ezetimibe 10
      mg once daily.

      The subjects in the intensive statin group will receive rosuvastatin 20 mg once daily.

      Subjects will visit at weeks 12 and 24 to identify medication adherence and clinical side
      effects.

      The primary endpoint of this study is a % change of low-density lipoprotein cholesterol at 12
      weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2018</start_date>
  <completion_date type="Actual">September 17, 2019</completion_date>
  <primary_completion_date type="Actual">June 15, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% change of low-density lipoprotein cholesterol</measure>
    <time_frame>at 12 weeks</time_frame>
    <description>%change of LDL-C = (LDL-C at 12 weeks) - (LDL-C at baseline)/LDL-C at baseline * 100</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>% change of serum cholesterol level</measure>
    <time_frame>at 12 and 24 weeks</time_frame>
    <description>total cholesterol, LDL, HDL cholesterol, triglyceride (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% change of high-sensitivity C-reactive protein</measure>
    <time_frame>at 12 and 24 weeks</time_frame>
    <description>hs-CRP(mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% change of fasting glucose</measure>
    <time_frame>at 12 and 24 weeks</time_frame>
    <description>fasting plasma glucose(mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% change of homeostatic model assessment for insulin resistance(HOMA-IR)</measure>
    <time_frame>at 12 and 24 weeks</time_frame>
    <description>HOMA-IR = glucose * insulin / 405(glucose mg/dL , insulin uIU/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of participant with statin-associated muscle symptoms</measure>
    <time_frame>at 12 and 24 weeks</time_frame>
    <description>occurrence of statin-associated muscle symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of participant with creatinine phosphokinase elevation</measure>
    <time_frame>at 12 and 24 weeks</time_frame>
    <description>proportion of CPK elevation ≥4 or ≥10 upper normal of limit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of participant with liver function test abnormality</measure>
    <time_frame>at 12 and 24 weeks</time_frame>
    <description>proportion of AST/ALT elevation ≥4 or ≥10 upper normal of limit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of participant with major adverse cardiovascular and cerebrovascular events(MACCE)</measure>
    <time_frame>at 12 and 24 weeks</time_frame>
    <description>MACCE defined as a composite of the followings : cardiovascular death, acute myocardial infarction, unstable angina, stroke</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">270</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>combination therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The combination therapy group will receive a single-pill combination of rosuvastatin 10 mg and ezetimibe 10 mg once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intensive statin group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The subjects in the intensive statin group will receive rosuvastatin 20 mg once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin</intervention_name>
    <description>This study is a multicenter, randomized, open-label, parallel, phase IV trial. The study is planned to include 272 patients with clinical ASCVD requiring optimal statin therapy.
After enrollment, subjects are randomized into two groups in a 1:1 manner. patients in combination therapy group(rosuvastation 10mg and ezetimibe 10mg daily) will be provided a fixed-dose single pill comibation and patients in the intensive statin group will receive rosuvastatin 20mg daily.</description>
    <arm_group_label>combination therapy group</arm_group_label>
    <arm_group_label>intensive statin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged between 19 and 75 years

          2. Presence of atherosclerotic cardiovascular disease Coronary artery disease

               -  History of acute coronary syndrome

               -  Stable or unstable angina

               -  History of coronary revascularization Stroke or TIA Peripheral arterial disease,
                  history of peripheral arterial revascularization

          3. Patients who have been taking lipid-lowering agents (statin or ezetimibe) for ≥4 weeks
             at the time of randomization

          4. Patients who gave informed consent

        Exclusion Criteria:

          1. Patients who have used lipid-lowering agents other than statin or ezetimibe within the
             last 3 months

          2. A serum triglyceride on fasting &gt;400 mg/dL

          3. A history of muscular symptoms or rhabdomyolysis due to the use of statin

          4. Hypersensitivity to rosuvastatin or ezetimibe

          5. Labeled contraindications to rosuvastatin or rosuvastatin Severe renal impairment
             (CrCl &lt;30 mL/min by Cockcroft-Gault formula or estimated GFR &lt;30 mL/min / 1.73 m2 by
             MDRD equation) ALT, AST ≥3 × ULN or active liver disease CPK ≥3 × ULN

          6. Enrollment of other clinical trials within 30 days

          7. Any other issues that the treating physician assumes ineligible for participation in
             the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>06511</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 28, 2019</study_first_submitted>
  <study_first_submitted_qc>September 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Si-Hyuck Kang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

